Company profile
Instil Bio, Inc.
NASDAQ: TIL · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
36DFH 46DQ 20GM —SS 38
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$71.4M
Employees
17
as of 2026-08-19
Market cap
$49.6M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02021
Net income-$71.4M-$71.4M2025
Operating income-$78.6M-$78.6M2025
Total assets$203.5M$203.5M2025
Liabilities$89.7M$89.7M2025
Equity$113.9M$113.9M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Instil Bio, Inc.’s revenue?
Instil Bio, Inc. booked $0 in FY2021 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Eloxx Pharmaceuticals, Inc.29DEdesa Biotech, Inc.47DArch Biopartners Inc.13DTenax Therapeutics, Inc.49DNoveris Health Sciences Inc.——Grace Therapeutics, Inc.48DNeighbors
Dallas →Key facts
CEOBronson Crouch
SectorHealthcare
IndustryBiotechnology
HeadquartersDallas, TX
ExchangeNASDAQ: TIL
Employees17
IPO date2021-03-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.